Skip to Content

Viaskin Peanut Approval Status

FDA Approved: No
Brand name: Viaskin Peanut
Generic name: peanut immunotherapy
Company: DBV Technologies
Treatment for: Peanut Allergy

Viaskin Peanut is an immunotherapeutic skin patch in development for use in the treatment of peanut allergy.

Development Status and FDA Approval Process for Viaskin Peanut

DateArticle
Dec 19, 2018DBV Technologies Provides Update on Viaskin Peanut for Children Four to 11 Years of Age - BLA Withdrawn
Nov 20, 2018DBV Technologies Presents Data at ACAAI 2018 on Investigational Viaskin Peanut for the Treatment of Peanut-Allergic Children
Oct 22, 2018DBV Technologies Announces Submission of Biologics License Application for Viaskin Peanut to the U.S. Food and Drug Administration
Aug  2, 2012DBV Technologies initiates VIPES phase IIb clinical study, the first global trial ever in desensitization of peanut-allergic children and adults
Feb 29, 2012Clinical Development Program receives FDA "Fast Track Designation" and encouraging phase Ib safety results for Viaskin Peanut

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide